VolitionRx Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de VolitionRx de 47.5% y 54.8% respectivamente, mientras que el BPA crecerá en un 50.5% al año.

Información clave

47.5%

Tasa de crecimiento de los beneficios

50.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.2%
Tasa de crecimiento de los ingresos	54.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	23 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

What Type Of Shareholders Own The Most Number of VolitionRx Limited (NYSEMKT:VNRX) Shares?

Nov 30

Previsiones de crecimiento de beneficios e ingresos

NYSEAM:VNRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	61	-5	-1	0	3
12/31/2025	16	-32	-26	-25	4
12/31/2024	4	-36	-31	-29	4
12/31/2023	1	-35	-19	-18	N/A
9/30/2023	1	-34	-32	-30	N/A
6/30/2023	1	-33	-30	-29	N/A
3/31/2023	0	-31	-29	-28	N/A
12/31/2022	0	-30	-17	-15	N/A
9/30/2022	0	-31	-15	-14	N/A
6/30/2022	0	-30	-13	-12	N/A
3/31/2022	0	-28	-12	-11	N/A
12/31/2021	0	-27	-22	-21	N/A
9/30/2021	0	-24	-21	-19	N/A
6/30/2021	0	-21	-21	-19	N/A
3/31/2021	0	-21	-20	-18	N/A
12/31/2020	0	-20	-18	-16	N/A
9/30/2020	0	-19	-17	-16	N/A
6/30/2020	0	-19	-16	-16	N/A
3/31/2020	0	-18	-15	-14	N/A
12/31/2019	0	-16	-13	-13	N/A
9/30/2019	0	-17	-14	-14	N/A
6/30/2019	N/A	-17	-15	-15	N/A
3/31/2019	N/A	-18	-15	-15	N/A
12/31/2018	N/A	-18	-15	-15	N/A
9/30/2018	N/A	-18	-15	-15	N/A
6/30/2018	N/A	-17	-14	-13	N/A
3/31/2018	N/A	-16	-14	-13	N/A
12/31/2017	N/A	-15	-14	-12	N/A
9/30/2017	N/A	-14	N/A	-10	N/A
6/30/2017	N/A	-13	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-12	N/A	-9	N/A
9/30/2016	N/A	-12	N/A	-9	N/A
6/30/2016	N/A	-11	N/A	-9	N/A
3/31/2016	N/A	-10	N/A	-9	N/A
12/31/2015	N/A	-10	N/A	-9	N/A
9/30/2015	0	-8	N/A	-7	N/A
6/30/2015	N/A	-11	N/A	-6	N/A
3/31/2015	N/A	-8	N/A	-5	N/A
12/31/2014	N/A	-8	N/A	-4	N/A
9/30/2014	0	-8	N/A	-4	N/A
6/30/2014	N/A	-3	N/A	-4	N/A
3/31/2014	N/A	-5	N/A	-4	N/A
12/31/2013	N/A	-4	N/A	-3	N/A
9/30/2013	N/A	-4	N/A	-3	N/A
6/30/2013	0	-4	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que VNRX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que VNRX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que VNRX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (54.8% al año) de VNRX crezcan más rápidamente que los del mercado US (7.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (54.8% al año) de VNRX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VNRX se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

VolitionRx Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates fall by 43%

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 22%, EPS upgraded

Price target increased by 7.2% to US$3.66

Consensus revenue estimates decrease by 45%

Forecast to breakeven in 2025

Recent updates

VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech

Consensus revenue estimates fall by 43%

New minor risk - Profitability

Forecast to breakeven in 2026

Full year 2023 earnings: EPS and revenues miss analyst expectations

VolitionRx Limited announced that it has received $0.1 million in funding

Volitionrx Limited Appoints Andrew Retter as Chief Medical Officer, Effective April 1, 2024

High number of new directors

VolitionRx Limited announced that it has received €2.5 million in funding

Consensus revenue estimates decrease by 22%, EPS upgraded

New major risk - Negative shareholders equity

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 7.2% to US$3.66

VolitionRx Limited Presents Breakthrough Liquid Biopsy Blood Test Method for Early-Stage Cancer

New minor risk - Profitability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $16.51 million.

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $16.51 million.

Consensus revenue estimates decrease by 45%

Forecast to breakeven in 2025

Price target decreased by 11% to US$4.94

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $7.525 million.

Price target decreased by 9.7% to US$5.21

Chief Scientific Officer recently bought US$72k worth of stock

Volitionrx Limited Announces Resignation of Dr. Jason Terrell as Chief Medical Officer

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Volition Announces the Launch of the Nu.Q(R) Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

Consensus revenue estimates fall by 19%

VolitionRx Limited Appoints Mickie Henshall as Independent Director

Price target decreased to US$6.71

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 94%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

VolitionRx Limited Launches its Nu.Q® Vet Cancer Test in Asia

VolitionRx Limited Appoints Sharon Ballesteros as U.S. Head of Quality and Development Process

Consensus revenue estimates increase by 253%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.092 loss in 3Q 2020)

Consensus revenue estimates fall to US$530.0k

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.12 loss in 2Q 2020)

VolitionRx Limited Demonstrates Promising Results in Covid-19 Risk Stratification and Disease Monitoring

VolitionRx Limited(NYSEAM:VNRX) dropped from Russell 3000E Value Index

Consensus forecasts updated

Lead Independent Director recently bought US$503k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2020)

Non-Executive Director has left the company

Consensus revenue estimates fall to US$903.7k

Full year 2020 earnings released: US$0.45 loss per share (vs US$0.41 loss in FY 2019)

Do Institutions Own VolitionRx Limited (NYSEMKT:VNRX) Shares?

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $20.000001 million.

Insider recently sold US$54k worth of stock

This Insider Has Just Sold Shares In VolitionRx Limited (NYSEMKT:VNRX)

New 90-day high: US$6.50

Volitionrx Limited Announces Executive Appointments

Price target raised to US$7.66

Market Sentiment Around Loss-Making VolitionRx Limited (NYSEMKT:VNRX)

New 90-day high: US$4.46

Have Insiders Been Selling VolitionRx Limited (NYSEMKT:VNRX) Shares This Year?

New 90-day high: US$3.79

VolitionRx Limited Appoints Dr. Tom Butera DVM to its Board of Directors, Audit, Compensation and Nominations and Governance Committees

Volition Launches Nu.Q Vet Cancer Screening Test in the U.S

What Type Of Shareholders Own The Most Number of VolitionRx Limited (NYSEMKT:VNRX) Shares?

VolitionRx Limited to Present COVID-19 Data at MEDICA 2020